Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

Detalles Bibliográficos
Autores principales: Cavalli, Giulio, Tomelleri, Alessandro, De Luca, Giacomo, Campochiaro, Corrado, Dinarello, Charles A., Baldissera, Elena, Dagna, Loreno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375123/
https://www.ncbi.nlm.nih.gov/pubmed/30760322
http://dx.doi.org/10.1186/s13075-019-1843-9
_version_ 1783395310479867904
author Cavalli, Giulio
Tomelleri, Alessandro
De Luca, Giacomo
Campochiaro, Corrado
Dinarello, Charles A.
Baldissera, Elena
Dagna, Loreno
author_facet Cavalli, Giulio
Tomelleri, Alessandro
De Luca, Giacomo
Campochiaro, Corrado
Dinarello, Charles A.
Baldissera, Elena
Dagna, Loreno
author_sort Cavalli, Giulio
collection PubMed
description
format Online
Article
Text
id pubmed-6375123
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63751232019-02-26 Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease Cavalli, Giulio Tomelleri, Alessandro De Luca, Giacomo Campochiaro, Corrado Dinarello, Charles A. Baldissera, Elena Dagna, Loreno Arthritis Res Ther Letter BioMed Central 2019-02-13 2019 /pmc/articles/PMC6375123/ /pubmed/30760322 http://dx.doi.org/10.1186/s13075-019-1843-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter
Cavalli, Giulio
Tomelleri, Alessandro
De Luca, Giacomo
Campochiaro, Corrado
Dinarello, Charles A.
Baldissera, Elena
Dagna, Loreno
Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
title Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
title_full Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
title_fullStr Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
title_full_unstemmed Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
title_short Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
title_sort efficacy of canakinumab as first-line biologic agent in adult-onset still’s disease
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375123/
https://www.ncbi.nlm.nih.gov/pubmed/30760322
http://dx.doi.org/10.1186/s13075-019-1843-9
work_keys_str_mv AT cavalligiulio efficacyofcanakinumabasfirstlinebiologicagentinadultonsetstillsdisease
AT tomellerialessandro efficacyofcanakinumabasfirstlinebiologicagentinadultonsetstillsdisease
AT delucagiacomo efficacyofcanakinumabasfirstlinebiologicagentinadultonsetstillsdisease
AT campochiarocorrado efficacyofcanakinumabasfirstlinebiologicagentinadultonsetstillsdisease
AT dinarellocharlesa efficacyofcanakinumabasfirstlinebiologicagentinadultonsetstillsdisease
AT baldisseraelena efficacyofcanakinumabasfirstlinebiologicagentinadultonsetstillsdisease
AT dagnaloreno efficacyofcanakinumabasfirstlinebiologicagentinadultonsetstillsdisease

Ejemplares similares